Feighner J P, Boyer W F, Hendrickson G G, Pambakian R A, Doroski V S
Feighner Research Institute, Encinitas, CA 92084.
Int Clin Psychopharmacol. 1990 Jul;5(3):227-32. doi: 10.1097/00004850-199007000-00008.
Thirty outpatients between the ages of 60 and 85 with DSM-III Major Depression entered an 8 week randomized, double-blind comparison of desipramine and adinazolam mesylate, a triazolobenzodiazepine derivative. Outcome was assessed on several measures including the Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Rating Scale, Clinical Global Impressions (CGI), the 35-item Self-Rating Symptom Scale, and Carroll Depression Scale. Patients in both groups demonstrated a highly significant decrease in average HDRS scores (p less than 0.001) over the course of the study. Adinazolam was associated with significantly greater reduction in average HDRS scores by the third day. Repeated measures analysis of variance showed a significantly greater reduction in HDRS scores for adinazolam over the course of the study. The study medications were associated with distinct patterns of adverse reactions. Desipramine more often produced dry mouth, constipation and nervousness, while adinazolam was more likely to cause drowsiness and lightheadedness. Three of these elderly patients, all of whom were taking desipramine reported at least one fall during the study. Adinazolam may be a promising agent in the treatment of depression in the elderly.
30名年龄在60至85岁之间、患有DSM-III重度抑郁症的门诊患者，参与了一项为期8周的地昔帕明与甲磺酸阿地唑仑（一种三唑并苯二氮䓬衍生物）的随机双盲对照试验。通过多项指标评估结果，包括汉密尔顿抑郁量表（HDRS）、蒙哥马利-阿斯伯格抑郁量表、临床总体印象量表（CGI）、35项自评症状量表和卡罗尔抑郁量表。在研究过程中，两组患者的平均HDRS评分均显著下降（p<0.001）。到第三天时，阿地唑仑组的平均HDRS评分下降更为显著。重复测量方差分析显示，在整个研究过程中，阿地唑仑组的HDRS评分下降幅度更大。研究药物出现了不同的不良反应模式。地昔帕明更常引起口干、便秘和紧张，而阿地唑仑更易导致嗜睡和头晕。这些老年患者中有3名，均服用地昔帕明，在研究期间至少报告了一次跌倒事件。阿地唑仑可能是治疗老年抑郁症的一种有前景的药物。
